Elegen Raises the Bar for Synthetic DNA by Lowering Prices Across Its ENFINIA™ Portfolio

Clonal, cell-free DNA with unmatched length, complexity and accuracy now available at industry-leading prices.

MENLO PARK, Calif.--(BUSINESS WIRE)--Elegen today announced significant price reductions across its ENFINIA™ DNA portfolio, now offering high-accuracy, clonal, cell-free synthetic DNA with list pricing as low as $0.07 per base pair.

“For years, researchers have been forced to choose between quality, speed, length, complexity and cost,” said Matthew Hill, Ph.D., Founder and CEO of Elegen. By removing these tradeoffs, customers can access clonal, cell-free DNA at the price of non-clonal fragments. This capability unlocks longer construct lengths and broader design flexibility while setting a new baseline for high-performance synthetic DNA. “We’re excited to enable faster experimental iteration, greater sequence diversity and improved economic efficiency for our customers,” Hill added.

The new pricing is made possible by the deployment of Elegen’s GEN II Cell-Free DNA Platform, incorporating Elegen’s innovative microfluidic synthesizer, another major advance in its production process, alongside Elegen’s existing high-complexity DNA build capabilities and highly optimized cell-free cloning technology. The GEN II platform redefines expectations for DNA synthesis—delivering superior sequence fidelity, length and complexity without the traditional tradeoffs of cost, speed and reliability.

New pricing highlights

• ENFINIA Linear DNA, up to 7 kb, in 6-8 days, as low as $0.07 per base pair.
• ENFINIA Plasmid DNA, rapid clonal genes up to 15 kb, as low as $0.12 per base pair.
• ENFINIA IVT Ready DNA, linear DNA with poly(A) tails, as low as $0.11 per base pair.
• Additional volume-based discounts available for bulk orders and strategic partnerships.

Elegen will share a technical deep dive into the architecture and performance of its GEN II Cell-Free DNA Platform during a February 10 webinar hosted by Genetic Engineering and Biotechnology News (GEN).

About Elegen

Elegen has redefined synthetic DNA manufacturing with proprietary cell-free technologies that deliver longer, higher-quality DNA at unprecedented speed, scale and now affordability. With its commercial GEN II DNA Production Platform and ENFINIA DNA product suite, Elegen accelerates scientific discovery and therapeutic innovation for customers around the world. Headquartered in Menlo Park, Calif., Elegen remains privately held and focused on expanding access to next-generation genetic tools.

For more information and updated ENFINIA DNA pricing, visit elegenbio.com and ecommerce.elegen.com. Connect with us on LinkedIn and X.